Weston family and Fairfax Financial agree to buy Boots for $8.9 billion

Fairfax Financial Holdings, the Toronto insurance and investment group run by Prem Watsa, agreed on Wednesday to join Wittington Investments, the holding company of Canada's Weston family, in an approximately US$8.9 billion purchase of Boots, the 177-year-old British pharmacy and beauty chain. The deal, announced jointly by the two buyers, ends five years of ownership drift, a shelved stock-market listing and a stop-start auction, and puts Britain's best-known high-street chemist under a single family owner with decades of grocery and pharmacy experience. Wittington will hold operational control. Fairfax is expected to own half of Boots' equity once the transaction closes. Galen Weston, who chairs Wittington and also leads Loblaw Companies and George Weston Limited, will become Boots' chairman.

The seller is Sycamore Partners, the New York private equity firm that has controlled Boots for barely more than a year. The sale removes the largest remaining piece of the business Sycamore picked up when it took the chain's former US parent, Walgreens Boots Alliance, private in 2025.

The numbers

According to the regulatory filing Fairfax made with US securities regulators, the total price is about US$8.9 billion, including assumed debt, which converts to roughly £6.7 billion. Fairfax has signed an equity commitment letter for up to US$2.3 billion of that total, in exchange for a 50 percent stake once the deal closes. The purchase covers Boots' retail operations in the UK and Ireland, Boots Opticians, the No7 Beauty Company, and Boots' business in Thailand and its franchised stores elsewhere. Two pieces of the wider group are carved out of the sale: Farmacias Benavides in Mexico and Alliance Healthcare Deutschland in Germany, which will stay with Sycamore and with Stefano Pessina's family, the chain's former owner-operators. The transaction is subject to customary closing conditions and is expected to complete in the first quarter of 2027.

Boots itself runs roughly 1,800 stores across the UK, and Sycamore's managing director, Stefan Kaluzny, said in the companies' statements that the business employs "more than 50,000 colleagues." Those numbers give a sense of scale next to the buyer: Loblaw, the Weston-controlled grocer, operates more than 2,800 Canadian locations and owns Shoppers Drug Mart, Canada's largest pharmacy chain, with roughly 1,350 outlets.

How Boots ended up changing hands twice in two years

Boots was founded in Nottingham in 1849 as a herbalist's shop and grew into a fixture of British retail, listed on the London Stock Exchange for more than a century. It left public markets in 2007, when it became the first blue-chip company taken private through a leveraged buyout, in a deal led by the Italian pharmacist Stefano Pessina alongside KKR. Pessina's business later merged with the American chain Walgreens in 2014 to form Walgreens Boots Alliance, which kept Boots as its UK arm for more than a decade.

That arrangement ended when Sycamore Partners completed its roughly US$24 billion take-private of Walgreens Boots Alliance in August 2025 and split the group into separate companies, re-establishing Boots as a standalone business under chief executive Ornella Barra. Sycamore then weighed two paths for Boots: relisting it on the London Stock Exchange or selling it outright. A sale process drew interest from the Australian pharmacy group Sigma Healthcare, which in June walked away from preliminary talks, saying a deal would not meet its strategic and financial goals. That left the Westons as the only bidder left at the table, and talks stalled over the summer after the family tried to lower its offer; negotiations ultimately came back together, culminating in Wednesday's announcement.

Who is affected

The immediate effect falls on Boots' UK workforce and its roughly 1,800 shops, which will keep operating as before while the sale works through regulatory clearance over the coming months; neither buyer has announced store closures, job cuts or management changes beyond the chairmanship. No7 Beauty Company, Boots' cosmetics brand, and Boots Opticians pass into the deal intact, while the group's operations in Mexico and Germany are being retained by Sycamore and the Pessina family rather than sold on.

Analysts see the shift in ownership as more consequential for strategy than for headcount in the near term. Neil Saunders of the retail research firm GlobalData told BNN Bloomberg that the Westons "understand retail and have a track record of growing businesses," and predicted gradual changes such as refreshed stores, more investment in beauty and a bigger push behind the No7 brand, alongside a stronger focus on wellness and diagnostics services.

Reaction

"We see a meaningful opportunity to make a great business even better," Galen Weston said of Boots, which he called "one of Britain's most enduring businesses, with a rich heritage, a trusted name," adding that the plan rests on "stable, long-term ownership, further capital investment and renewed operating focus."

Prem Watsa, Fairfax's chairman and chief executive, said in the companies' statement that he was "very pleased to partner with Galen Weston and the Wittington team" and that Fairfax was "very confident that Wittington will be an excellent steward of the Boots business." Sycamore's Kaluzny framed the sale as validation of the work done since the carve-out, saying the outcome was "a testament to the work" Boots' team had done as a standalone company.

What happens next

The companies expect the transaction to close in the first quarter of 2027, pending the usual regulatory sign-offs; no competition concerns have been flagged publicly so far, and the deal does not require Boots to combine operationally with Shoppers Drug Mart or any other Weston-controlled pharmacy business. Reporting on the stalled talks earlier this year suggested that, had the Westons walked away, Sycamore's fallback plan was to revisit a London listing for Boots in 2027; that alternative is now off the table unless the deal itself falls through before closing. For now, Boots will keep trading under its existing management, with the leadership handover limited to the chairmanship until the sale completes.